Press releases

Summary Financial overview January 1 – March 31, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 297.3 M (loss: 134.1) Loss per share, before and after dilution, was SEK 5.37 (loss: 2.82) On March 31 cash and cash equivalents amounted to SEK 617.8 M (747.5)

STOCKHOLM — May 22, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces a successful completion of enrollment in the pivotal phase 3 study OCEAN for the treatment of relapsed refractory multiple myeloma. The study includes 450 patients from more than 100 hospitals around the world. Top line results are expected to be presented later this year

STOCKHOLM — May 15, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that new pre-clinical data evaluating the potential of the lead candidate melflufen (melphalan flufenamide) have been selected for presentation at the American Association for Cancer Research (AACR). The poster presentations are now available online

STOCKHOLM — May 14, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that data from the pivotal phase 2 study HORIZON, and additional clinical and preclinical data that further evaluate the therapeutic peptide-drug conjugate platform, have been accepted by the European Hematology Association (EHA). The abstracts are now published online

STOCKHOLM — May 13, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that two abstracts with data in multiple myeloma have been accepted by the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. One of the abstracts relates to the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple myeloma (RRMM) patients. The abstracts are now available online

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR OTHER MEASURES

Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) hereby announces its intention to carry out a directed share issue to Swedish and international institutional investors (the “Directed Share Issue”). The Company has retained Carnegie, DNB Markets, Jefferies, Cowen and Kempen & Co to act as Joint Bookrunners (the “Joint Bookrunners”) in connection with the Directed Share Issue

Stockholm – April 28, 2020 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the annual report for 2019 is now available on the company's website. The report summarizes the company's business operations, strategy and financial results

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden, Tuesday 26 May 2020 at 2.00 p.m. Registration for attendees will commence at 1.30 p.m. Due to the current pandemic (COVID-19), Oncopeptides has taken a number of precautionary measures ahead of the Annual General Meeting aimed at keeping the meeting short and efficient and reduce the risk of spreading the virus. No food or drinks will be served before or after the Annual General Meeting. The CEO will not hold any address in the meeting venue, an address will instead be made available at Oncopeptides’ website on the day of the Annual General Meeting. Oncopeptides is encouraging all shareholders to vote in advance (see further information below)

STOCKHOLM — April 2, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Rolf Gulliksen has been appointed global head of corporate communications. Rolf has 30 years of experience from senior corporate communications roles in the life science industry and consultancy